165 related articles for article (PubMed ID: 22252581)
1. Cancer vaccines.
Nakamura Y
Clin Adv Hematol Oncol; 2011 Oct; 9(10):778-9. PubMed ID: 22252581
[No Abstract] [Full Text] [Related]
2. [New era of tumor immunotherapy].
Yoshitake Y; Nakatsura T; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
[No Abstract] [Full Text] [Related]
3. [Peptide-based vaccine therapy for cancer patients].
Yamada A
Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
[No Abstract] [Full Text] [Related]
4. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.
Oka Y; Sugiyama H
Immunotherapy; 2010 Sep; 2(5):591-4. PubMed ID: 20874639
[No Abstract] [Full Text] [Related]
5. [CTL precursor-oriented peptide vaccine therapy for malignant glioma].
Yajima N; Yamanaka R; Tanaka R; Shigemori M; Mine T; Itoh K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():582-7. PubMed ID: 16201585
[No Abstract] [Full Text] [Related]
6. Toll-like receptor ligands energize peptide vaccines through multiple paths.
Celis E
Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
[TBL] [Abstract][Full Text] [Related]
7. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.
Nishida S; Sugiyama H
Methods Mol Biol; 2016; 1467():221-32. PubMed ID: 27417973
[TBL] [Abstract][Full Text] [Related]
9. The delivery of effective therapeutic cancer vaccination.
Hart D
Asian J Androl; 2011 Mar; 13(2):183-4. PubMed ID: 21057515
[No Abstract] [Full Text] [Related]
10. Promising immunotherapy technique.
Fillon M
J Natl Cancer Inst; 2012 Oct; 104(20):1528-9. PubMed ID: 23044382
[No Abstract] [Full Text] [Related]
11. Advances in immuno-oncology. Foreword.
Eggermont A; Finn O
Ann Oncol; 2012 Sep; 23 Suppl 8():viii5. PubMed ID: 22918929
[No Abstract] [Full Text] [Related]
12. Cancer immunotherapy.
White RL; Amin A
Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
[TBL] [Abstract][Full Text] [Related]
13. Generation of dendritic cell-based vaccines for cancer therapy.
Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
[TBL] [Abstract][Full Text] [Related]
14. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
[TBL] [Abstract][Full Text] [Related]
15. Getting peptide vaccines to work: just a matter of quality control?
Celis E
J Clin Invest; 2002 Dec; 110(12):1765-8. PubMed ID: 12488425
[No Abstract] [Full Text] [Related]
16. Cytotoxic T lymphocytes: the future of cancer stem cell eradication?
Saijo H; Hirohashi Y; Torigoe T; Kochin V; Takahashi H; Sato N
Immunotherapy; 2013 Jun; 5(6):549-51. PubMed ID: 23725275
[No Abstract] [Full Text] [Related]
17. Are peptide vaccines viable in combination with other cancer immunotherapies?
Ohtake J; Sasada T
Future Oncol; 2017 Aug; 13(18):1577-1580. PubMed ID: 28776424
[No Abstract] [Full Text] [Related]
18. Immune monitoring in cancer immunotherapy.
Romero P; Pittet MJ; Valmori D; Speiser DE; Cerundolo V; Liénard D; Lejeune F; Cerottini JC
Ernst Schering Res Found Workshop; 2000; (30):75-97. PubMed ID: 10943317
[No Abstract] [Full Text] [Related]
19. Rethinking therapeutic cancer vaccines.
Nat Rev Drug Discov; 2009 Sep; 8(9):685-6. PubMed ID: 19721436
[No Abstract] [Full Text] [Related]
20. HER-2/neu as a target for cancer vaccines.
Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
